Luvometinib and Serplulimab for NF2-related tumors
Treatments studied
Part of Brain & nervous system, Cancer, Ear, nose & throat, Genetic & congenital clinical trials.
This trial tests a combination of two drugs (Luvometinib and Serplulimab) for people with NF2 (Neurofibromatosis type 2) who have growing brain tumors (vestibular schwannoma or meningioma) that cannot be safely removed with surgery. The goal is to see if this drug combination can shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with NF2 (Neurofibromatosis type 2).
- You need at least one measurable brain tumor (vestibular schwannoma or meningioma) that has grown in the past 3 years.
- This tumor must not be suitable for surgery because it would be too risky.
- You must be at least 18 years old.
- Your overall health (KPS or ECOG score) must be good enough for daily activities.
- Your blood tests (kidney, liver, blood cell counts) must be within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at new medicines for people with NF2-related schwannomatosis (NF2-SWN), a condition that causes tumors on nerves. It aims to track how tumors grow over time and test potential treatments.
This trial tests a drug called selumetinib for people with a rare genetic condition called NF2-related schwannomatosis, which causes non-cancerous tumors on nerves. The study focuses on shrinking or slowing the growth of these tumors, especially those affecting hearing, and is for patients who cannot have surgery or choose not to.
This trial studies targeted medicines in people with neurofibromatosis type 2 (NF2) who have growing tumors on scans. The goal is to slow tumor growth and improve symptoms by testing different drug combinations in separate study groups.
This trial tests a new drug called PRG-N-01 for people with Neurofibromatosis Type 2 (NF2) who have growing or symptomatic tumors but cannot have surgery. The goal is to find the best dose and see if the drug can help shrink or control the tumors.
This trial tests an oral drug called FCN-159 for people with NF2-related nerve sheath tumors that cannot be fully removed by surgery or have come back after surgery. It aims to see if the drug can shrink or slow the growth of these tumors.
This trial tests a gene therapy called ST002 for people with NF2-related tumors that cannot be treated with standard therapies or have not responded to them. The treatment is injected directly into a tumor, and the goal is to see if it can shrink or control the tumor.
Hear when a new Vestibular Schwannoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.